INTRODUCTION AND OBJECTIVES: Choriocarcinoma tumors of the testis are rare and usually present with significantly elevated HCG levels and hematogenous metastasis. When curable, it is felt to be largely a result of chemotherapy with little role for RPLND. We sought to determine the histologic characteristics for those undergoing PC-RPLND and compare them with metastatic NSGCT patients with similarly elevated HCG levels.
INTRODUCTION AND OBJECTIVES: Choriocarcinoma tumors of the testis are rare and usually present with significantly elevated HCG levels and hematogenous metastasis. When curable, it is felt to be largely a result of chemotherapy with little role for RPLND. We sought to determine the histologic characteristics for those undergoing PC-RPLND and compare them with metastatic NSGCT patients with similarly elevated HCG levels.
METHODS: We reviewed the medical records of men who underwent PC-RPLND between 1988-2017 with post-orchiectomy, preinduction chemotherapy HCG levels greater than 20,000 mU/mL. They were stratified by primary tumor histology into two groups: pure choriocarcinoma and mixed NSGCT. Clinical, pathologic and serologic data were reported and logistic regression was used to assess for predictors of necrosis /fibrosis in the PC-RPLND specimen.
RESULTS: Our cohort consisted of 152 men. The mixed group (N [129) had a median HCG of 108,001 mU/mL, a post chemotherapy node size of 4.45 cm, of whom 25.6% also received salvage chemotherapy prior to RPLND. The pure choriocarcinoma group (N[23) had a median HCG of 110,358 mU/mL, a post chemotherapy node size of 5.0 cm, of whom 30.4% received salvage chemotherapy prior to RPLND. In patients with pure choriocarcinoma, 87% had necrosis/fibrosis in the PC-RPLND specimen compared to only 29.5% of the mixed NSGCT group (p[ <0.0001, Figure 1 ). While controlling for receipt of salvage chemotherapy, prechemotherapy HCG levels, node size and marker status, pure choriocarcinoma patients were 20 fold more likely to have necrosis on RPLND specimen compared to mixed NSGCT group ). Of importance, 4 additional major procedures were performed concomitantly with PC-RPLND in the pure choriocarcinoma group (2 pulmonary resections, 1 hepatic wedge resection and 1 nephrectomy), 100% of which had necrosis in the final RPLND pathology. This contrasts with the mixed NSGCT group in that of the 48 patients who required additional procedures, only 8.3% were done in the setting of necrosis in the final RPLND specimen.
CONCLUSIONS: While PC-RPLND is appropriate in patients with residual masses after chemotherapy, patients with pure choriocarcinoma presenting with significantly elevated HCG levels represent a unique patient population where necrosis is found more often than anticipated.
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MP73-04 DIFFERENCES IN SEMEN PARAMETERS BETWEEN PATIENTS WITH TESTICULAR CANCER AND OTHER MALIGNANCIES USING VARIOUS CUT-OFF VALUES
Itsuto Hamano*, Shingo Hatakeyama, Rika Nakamura, Rie Fukuhara, Daisuke Noro, Toshikazu Tanaka, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Hirosaki, Japan; Takuya Koie, Gifu, Japan; Yoshihito Yokoyama, Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: Which parameters have impact on outcomes of subsequent intracytoplasmic sperm injection (ICSI) in TC patients remains unclear. This study aimed to compare semen parameters between patients with TC and other malignancies using various cutoff values and evaluate the correlation between semen parameters and ICSI outcomes.
METHODS: We retrospectively investigated semen parameters before cancer treatment in 117 patients with malignancies who cryopreserved sperms at our hospital between November 1999 and May 2016. We compared semen parameters between patients with TC and other malignancies (non-TC), seminoma and nonseminoma, and stage I TC and stage II/III TC. The assessment of cutoff values recommended by the World Health Organization and the total motile sperm count was performed between the TC and non-TC groups. The ICSI outcomes in those using preserved sperm were assessed. RESULTS: Of the 111 patients enrolled, 29 (26%) had TC and 82 (74%) had non-TC. Patients with TC demonstrated significantly lower total sperm concentration than non-TC patients. The cutoff value of total sperm concentration distinguished the patient proportions exceeding the cutoff between patients with TC (41%) and non-TC (66%). The comparison between patients with seminoma vs. nonseminoma and stage I vs. stage II/III TC presented no significant differences in semen parameters. We observed no correlation between pretreatment semen parameters and ICSI outcomes.
CONCLUSIONS: Although TC patients exhibited lower total sperm concentration, ICSI outcomes were acceptable. Further studies on the fertility potential of TC patients are warranted.
